Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Blood (2025) 146 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2025-1019

Published: 2025

Journal Articles

Predicting algorithm for GRFS after allogeneic hematopoietic stem cell transplantation: A study by the SFGM-TC

Estelle Hamon, Mihaela Juganaru, Guillaume Muller, Hélène Labussière-Wallet, Vincent Alcazer, Martin Carre, Jacques-Olivier Bay, Elisabeth Daguenet, Jerome Cornillon

Blood (2025) 146 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2025-4299

Published: 2025

Journal Articles

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Anne Huynh, Romain Buono, Edouard Forcade, Hélène Labussière, Patrice Ceballos, Jerome Cornillon, Quentin Cabrera, Maud D'Aveni, Amine Belhabri, Marie Robin, Raynier Devillier, Nicole Raus, Mauricette Michallet

Blood (2025) 146 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2025-4297

Published: 2025

Journal Articles

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Chloe Cote, Mael Heiblig, Urbain Tauveron-Jalenques, Martin Carre, Amine Belhabri, Gaspar Aspas Requena, Sylvain Lamure, Ugo Thévenet, Clemence Santana, Adrien Contejean, Jerome Cornillon, Elisabeth Daguenet, Pascale Flandrin-Gresta, Emmanuelle Tavernier

Blood (2025) 146 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2025-3442

Published: 2025

Journal Articles

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Blood (2025) 146 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2025-3398

Published: 2025

Journal Articles

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Blood (2025) 146 (Supplement 1): 6080.

https://doi.org/10.1182/blood-2025-6080

Published: 2025

Journal Articles

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Tiy Morris, Amandine Fayard, Vivien Dupont, Elisabeth Daguenet, Catherine Thieblemont, Emmanuel Bachy, Guillaume Manson, Charles Herbaux, Ibrahim Yakoub-Agha, Thomas Gastinne, Didier Blaise, Louise Roulin, François-Xavier Gros, Pierre Bories, Roch Houot, Steven Le Gouill, Elisabeth Botelho-Nevers, Ludovic Fouillet, Jerome Cornillon

Blood (2025) 146 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2025-1014

Published: 2025

Journal Articles

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

Blood (2025) 146 (Supplement 1): 2450.

https://doi.org/10.1182/blood-2025-2450

Published: 2025

Journal Articles

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Adrien Contejean, Pierre Chauvelot, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Clémence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Gian Matteo Pica, Arthur Dony, Amine Belhabri, Mauricette Michallet, Zofia Gross, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2024-207605

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Urbain Tauveron-Jalenques, Zofia Gross, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Adrien Contejean, Clemence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Pica Gian-Matteo, Dony Arthur, Amine Belhabri, Mauricette Michallet, Pedro Chorao, Mael Heiblig, Gaspar Aspas Requena

Blood (2024) 144 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2024-208577

Published: 2024

Journal Articles

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Mael Heiblig, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Martin Carre, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Zofia Gross

Blood (2024) 144 (Supplement 1): 846.

https://doi.org/10.1182/blood-2024-207764

Published: 2024

Journal Articles

Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study

Blood (2024) 144 (Supplement 1): 596.

https://doi.org/10.1182/blood-2024-194780

Published: 2024

Journal Articles

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Martin Carre, Mathieu Meunier, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2024-208817

Published: 2024

Journal Articles

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2024) 144 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2024-198603

Published: 2024

Journal Articles

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2024) 144 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2024-203964

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Emmanuelle Tavernier, Jérôme Cornillon, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carré, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2024-203496

Published: 2024

Journal Articles

Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2024) 144 (Supplement 1): 4946.

https://doi.org/10.1182/blood-2024-212055

Published: 2024

Journal Articles

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Blood (2024) 144 (4): 445–456.

https://doi.org/10.1182/blood.2023022273

Published: 2024

Includes: Supplemental data

Journal Articles

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Martin Carre, Mathieu Meunier, Emmanuelle Tavernier, Jérôme Cornillon, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Boullanger FOW HENG Nadine, Daciana Claudia Antal, Gian Matteo Pica, Dony Arthur, Clémence Santana, Clement Rocher, Mael Heiblig

Blood (2023) 142 (Supplement 1): 590.

https://doi.org/10.1182/blood-2023-187331

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Predicting algorithm for GRFS after allogeneic hematopoietic stem cell transplantation: A study by the SFGM-TC

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only